Difference between revisions of "Tivozanib (Fotivda)"
Jump to navigation
Jump to search
m (Jwarner moved page Tivozanib (AV-951) to Tivozanib (Fotivda): EMA approval with brand name) |
|||
| Line 6: | Line 6: | ||
==History of changes in FDA approval== | ==History of changes in FDA approval== | ||
| − | + | *3/10/2021: Approved for adult patients with relapsed or refractory advanced [[renal cell carcinoma|renal cell carcinoma (RCC)]] following two or more prior systemic therapies. | |
==Also known as== | ==Also known as== | ||
Revision as of 21:50, 10 March 2021
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.
Diseases for which it is used
History of changes in FDA approval
- 3/10/2021: Approved for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
Also known as
- Code name: AV-951
- Brand name: Fotivda